I read with concern about the outbreak of Ebola virus in Uganda, near the Democratic Republic of Congo. I wanted to offer my company's services. We believe that two well-known classes of blood pressure pills may actually be a kind of general viral antidote (1), effective even against Ebola. Although we have no experience with Ebola per se, we have observed an approximately 80% treatment success rate against West Nile virus encephalitis in humans, horses, and birds. The first 8 human patients were published in 2004 (2). Our approach appears to work for many common diseases (3), including sickle cell disease (4). To publicize news about our possible treatment for viral diseases, including HIV, I'm co-organizing a conference on "Cytokines" to be held in May, 2008 in The Gambia (http://mangosee.com/mangosteen/2008/cyt2008/cyt2008.htm). I would be extremely honored to collaborate with any physician in Uganda (or elsewhere) to test our hypothesis. The drugs we use are already stocked in every drugstore on earth, I'm quite sure. Yours sincerely, Dave Moskowitz MD References 1: ACE inhibitors and ARBs (angiotensin II receptor blockers) may turn out to be general viral antidotes, as described in Section 2151 of the Project BioShield II Act of April 28, 2005 (http://www.govtrack.us/congress/billtext.xpd?bill=s109-975), reproduced below:

CHAPTER 5--REPORT AND ADMINISTRATION

SEC. 2151. REPORT TO CONGRESS. Not later than 180 days after the date of enactment of this Act, the Director of the Centers for Disease Control and Prevention, in consultation with the Assistant Secretary for Medical Readiness and Response of the Department of Homeland Security and the Director of the National Institute for Allergy and Infectious Disease of the National Institutes of Health, shall submit a report to Congress that describes alternatives to traditional vaccines and anti-viral therapeutics for viral diseases, including negative immunomodulation compounds that partially suppress a macrophage-dependent innate immune response of an individual to viral pathogens, in order to decrease morbidity and mortality from an excessive immune response.

2: Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem. 2004;4(13):1433-54. PMID: 15379656 (For PDF file, click on paper #6 at: http://www.genomed.com/index.cfm?action=investor&drill=publications) 3: Moskowitz DW. Is angiotensin I-converting enzyme a "master" disease gene? Diabetes Technol Ther. 2002;4(5):683-711. PMID: 12458570 (For PDF file, click on paper #2 at: http://www.genomed.com/index.cfm?action=investor&drill=publications) 4. Williams RM, Moskowitz DW. The prevention of pain from sickle cell disease using trandolapril. J Natl Med Assoc 2007 Mar; 99(3):276-8 http://www.nmanet.org/images/uploads/Publications/CR0276.pdf)

************************************** David W. Moskowitz, MD, MA(Oxon.), FACP Chairman, CEO & Chief Medical Officer GenoMed, Inc. "Our business is public health(TM)" 9666 Olive Blvd., Suite 310 St. Louis, MO 63132 website: www.genomed.com Ticker symbol: GMED (on the OTC Pinksheets) email: dwmoskowitz@genomed.com